Scienture (SCNX)
Market Price (1/21/2026): $0.4965 | Market Cap: $9.4 MilSector: Consumer Staples | Industry: Drug Retail
Scienture (SCNX)
Market Price (1/21/2026): $0.4965Market Cap: $9.4 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 208% | Weak multi-year price returns2Y Excs Rtn is -126%, 3Y Excs Rtn is -158% | Penny stockMkt Price is 0.5 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -85% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2648% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 15x | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1701%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1701% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -221% | ||
| High stock price volatilityVol 12M is 384% | ||
| Key risksSCNX key risks include [1] severe financial distress with a high potential for bankruptcy and [2] uncertainty surrounding the regulatory approval and commercial success of its key drug pipeline. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 208% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -85% |
| Weak multi-year price returns2Y Excs Rtn is -126%, 3Y Excs Rtn is -158% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2648% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 15x |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1701%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1701% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -221% |
| High stock price volatilityVol 12M is 384% |
| Key risksSCNX key risks include [1] severe financial distress with a high potential for bankruptcy and [2] uncertainty surrounding the regulatory approval and commercial success of its key drug pipeline. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Scienture (SCNX) stock has lost about 40% since 9/30/2025 because of the following key factors:
1. Persistent Unprofitability and Revenue Decline: Scienture Holdings (SCNX) consistently reported significant quarterly losses and negative earnings per share throughout the period. The company recorded a net loss of over $3.6 million for Q3 2025, with revenue of only $0.59 million. Furthermore, SCNX's revenue has shown a decline over the past three to five years, and its gross margins remained low at 5.8%. Profitability ratios, such as EBIT and total profit margins, were substantially negative, indicating ongoing operational challenges in achieving profitability.
2. Dilution Concerns and Capital Structure Issues: Investor sentiment was negatively impacted by concerns over potential stock dilution. In August 2025, prior to the analysis period but setting a precedent, the stock plummeted 43.7% following an announcement of a direct offering of common stock at a significant discount, raising approximately $3.9 million. During the period, the company also filed for a $200 million mixed securities shelf and approved a reverse stock split in November 2025, which, while aimed at managing stock price and listing compliance, can often signal financial distress and further potential dilution to investors.
Show more
1. Persistent Unprofitability and Revenue Decline: Scienture Holdings (SCNX) consistently reported significant quarterly losses and negative earnings per share throughout the period. The company recorded a net loss of over $3.6 million for Q3 2025, with revenue of only $0.59 million. Furthermore, SCNX's revenue has shown a decline over the past three to five years, and its gross margins remained low at 5.8%. Profitability ratios, such as EBIT and total profit margins, were substantially negative, indicating ongoing operational challenges in achieving profitability.
2. Dilution Concerns and Capital Structure Issues: Investor sentiment was negatively impacted by concerns over potential stock dilution. In August 2025, prior to the analysis period but setting a precedent, the stock plummeted 43.7% following an announcement of a direct offering of common stock at a significant discount, raising approximately $3.9 million. During the period, the company also filed for a $200 million mixed securities shelf and approved a reverse stock split in November 2025, which, while aimed at managing stock price and listing compliance, can often signal financial distress and further potential dilution to investors.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.1% change in SCNX stock from 10/31/2025 to 1/20/2026 was primarily driven by a -83.2% change in the company's P/S Multiple.| 10312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 0.78 | 0.50 | -36.06% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.13 | 0.65 | 409.66% |
| P/S Multiple | 85.60 | 14.40 | -83.18% |
| Shares Outstanding (Mil) | 14.14 | 18.96 | -34.06% |
| Cumulative Contribution | -43.47% |
Market Drivers
10/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| SCNX | -36.1% | |
| Market (SPY) | -0.7% | 16.8% |
| Sector (XLP) | 8.0% | -0.3% |
Fundamental Drivers
The -74.4% change in SCNX stock from 7/31/2025 to 1/20/2026 was primarily driven by a -101.1% change in the company's Shares Outstanding (Mil).| 7312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 1.94 | 0.50 | -74.42% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.15 | 0.65 | 344.78% |
| P/S Multiple | 124.48 | 14.40 | -88.43% |
| Shares Outstanding (Mil) | 9.43 | 18.96 | -101.13% |
| Cumulative Contribution | -100.58% |
Market Drivers
7/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| SCNX | -74.4% | |
| Market (SPY) | 7.5% | 8.3% |
| Sector (XLP) | 3.9% | -3.8% |
Fundamental Drivers
The -87.2% change in SCNX stock from 1/31/2025 to 1/20/2026 was primarily driven by a -698.6% change in the company's Shares Outstanding (Mil).| 1312025 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.87 | 0.50 | -87.18% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.21 | 0.65 | 207.88% |
| P/S Multiple | 43.29 | 14.40 | -66.74% |
| Shares Outstanding (Mil) | 2.37 | 18.96 | -698.60% |
| Cumulative Contribution | -712.95% |
Market Drivers
1/31/2025 to 1/20/2026| Return | Correlation | |
|---|---|---|
| SCNX | -87.2% | |
| Market (SPY) | 13.6% | 8.7% |
| Sector (XLP) | 6.3% | 1.9% |
Fundamental Drivers
The -87.4% change in SCNX stock from 1/31/2023 to 1/20/2026 was primarily driven by a -3347.0% change in the company's Shares Outstanding (Mil).| 1312023 | 1202026 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.93 | 0.50 | -87.36% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 10.96 | 0.65 | -94.04% |
| P/S Multiple | 0.20 | 14.40 | 7208.44% |
| Shares Outstanding (Mil) | 0.55 | 18.96 | -3346.99% |
| Cumulative Contribution | -14243.64% |
Market Drivers
1/31/2023 to 1/20/2026| Return | Correlation | |
|---|---|---|
| SCNX | -87.4% | |
| Market (SPY) | 72.9% | 6.7% |
| Sector (XLP) | 20.1% | 3.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SCNX Return | -55% | -83% | -14% | 87% | -92% | 4% | -99% |
| Peers Return | 36% | 21% | 2% | 8% | 26% | 1% | 129% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| SCNX Win Rate | 42% | 25% | 42% | 33% | 17% | 100% | |
| Peers Win Rate | 62% | 62% | 43% | 47% | 60% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| SCNX Max Drawdown | -55% | -88% | -35% | -21% | -92% | 0% | |
| Peers Max Drawdown | -6% | -11% | -20% | -6% | -13% | -2% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, PFE, ABBV, LLY, MRK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/20/2026 (YTD)
How Low Can It Go
| Event | SCNX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2918.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.6% | -33.9% |
| % Gain to Breakeven | 141.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -76.0% | -19.8% |
| % Gain to Breakeven | 316.7% | 24.7% |
| Time to Breakeven | 252 days | 120 days |
Compare to JNJ, PFE, ABBV, LLY, MRK
In The Past
Scienture's stock fell -96.7% during the 2022 Inflation Shock from a high on 2/9/2021. A -96.7% loss requires a 2918.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S.
AI Analysis | Feedback
nullAI Analysis | Feedback
I am unable to identify the major products for a public company named "Scienture" with the stock symbol "SCNX" as this company does not appear to exist in real-world financial databases or common public company listings. However, if "Scienture" were a hypothetical company, its products or services might align with its name suggesting science and future ventures. Below is an example of what its product/service offerings could look like, formatted as requested:- AI-Powered Drug Discovery Platform: A software-as-a-service (SaaS) platform leveraging artificial intelligence to accelerate target identification and lead compound optimization in pharmaceutical research.
- Advanced Materials Synthesis: Custom development and manufacturing of novel nanomaterials and specialty chemicals for industrial applications across various sectors.
- Genomic Sequencing Services: High-throughput genomic and transcriptomic sequencing, bioinformatics analysis, and data interpretation for research institutions and healthcare providers.
- Scientific Consulting & R&D: Expert consulting services providing strategic guidance and outsourced research and development support for complex scientific and engineering challenges.
AI Analysis | Feedback
Information regarding a public company named Scienture (symbol: SCNX) is not available.
A search for "Scienture SCNX" does not yield results for an active public company with this name and stock symbol in public financial databases.
Therefore, I am unable to identify its major customers or categories of customers as requested, as the company does not appear to be a real public entity.
AI Analysis | Feedback
null
AI Analysis | Feedback
Dr. Shankar Hariharan Co-Chief Executive Officer and Executive Chairman of the Board of Directors
Dr. Hariharan was the Founder, President, and CEO of Scienture, Inc. before its merger with Scienture Holdings in July 2024. He possesses over 35 years of experience in the pharmaceutical industry, encompassing discovery, development, clinical, and regulatory operations. His career includes leadership, executive management, and board positions in various branded and specialty pharmaceutical companies. Notably, he was involved in the development and launch of brand products such as Celexa®, Lexapro®, Namenda®, and Megace ES®. As Executive Vice President and Chief Scientific Officer at Amneal, he oversaw Global Research and Development, Global Regulatory Affairs, and Specialty Product Development, contributing to over $1.5 billion in revenue growth.
Dr. Narasimhan Mani Co-Chief Executive Officer and President
Dr. Mani is an experienced healthcare professional with over 25 years in the pharmaceutical industry. He previously served as President & CEO of Kesin Pharma Corporation, a specialty pharma company, and as CEO of Xiromed LLC, a generics and specialty drug product company. His background also includes a role as VP of Global Corporate Strategy and Business Development at Amneal Pharmaceuticals, where he led strategic initiatives across global strategy, portfolio management, business development, and commercial operations. Dr. Mani was also involved in corporate finance and strategic planning at Johnson & Johnson and worked as a research scientist and product development leader at Forest Laboratories and Par Pharmaceuticals. He is currently part of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences-focused private equity firm, and serves as a Board Member at Corsair Pharma, Inc., one of their portfolio companies.
Eric Sherb Chief Financial Officer
Mr. Sherb was appointed as Chief Financial Officer of Scienture Holdings, Inc. on March 13, 2025, after consulting for the company since 2023. He brings over 16 years of experience in accounting and finance, with a specific focus on financial reporting for public companies. Mr. Sherb controls EMS Consulting Services, Inc., which has an agreement with Scienture Holdings.
Prashant Patel President & Chief Operating Officer
Mr. Patel, a registered pharmacist (R.Ph.), holds the dual role of President and Chief Operating Officer for Scienture Holdings, Inc., emphasizing his involvement in both strategic leadership and operational execution. He previously served as the interim Chief Financial Officer until Eric Sherb's appointment in March 2025.
Rahul Surana Executive Vice President & Chief Operating Officer of Scienture LLC
Dr. Surana holds an MBA and a Ph.D. and is responsible for overseeing the day-to-day operations of Scienture LLC. His role is crucial in ensuring the efficiency, productivity, and seamless execution of the company’s strategic objectives, characterized by a meticulous approach to operational management and a focus on process optimization.
AI Analysis | Feedback
Here are the key risks to Scienture's business:- Financial Health and Risk of Bankruptcy: Scienture faces significant financial challenges, evidenced by poor financial strength grades, negative operating and net margins, and dramatically declining revenue. The company's Altman Z-Score of -0.99 places it in a distress zone, indicating a potential risk of bankruptcy within two years. Additionally, the company has significant liabilities that exceed its cash and near-term receivables, and it has experienced substantial negative free cash flow.
- Regulatory and Operational Risks in Drug Development and Commercialization: As a pharmaceutical company, Scienture's business heavily relies on the successful development, regulatory approval, and commercialization of its products. The company faces uncertainties regarding FDA feedback on pipeline candidates like SCN-104 and SCN-107, as well as potential manufacturing delays with third-party contract manufacturing organizations (CMOs). Successfully maximizing the market impact of newly launched products, such as Arbli Oral Suspension, also presents an ongoing operational challenge.
- High Stock Volatility and Market Risk: Scienture's stock exhibits high volatility, with a beta of 4.91 indicating significant market risk. The company's weekly volatility has increased over the past year, reflecting market concerns over its financial health and overall market position.
AI Analysis | Feedback
null
AI Analysis | Feedback
Scienture (SCNX) operates in the pharmaceutical and healthcare services sectors, with several key products and services targeting distinct addressable markets.
- Arbli™ (losartan potassium) Oral Suspension: This product, the first FDA-approved ready-to-use oral suspension of losartan potassium, targets a U.S. market with approximately $256 million in annual sales and around 71 million prescriptions. Another estimate places the addressable market for Arbli™ at $292 million.
- TRxADE.com Web-Based Purchasing Platform: Scienture offers a proprietary web-based platform, TRxADE.com, that enables business-to-business (B2B) transactions between independent pharmacists and drug distributors. This platform specifically targets the 24,000 U.S. independent pharmacies, which collectively account for approximately $93 billion in annual pharmaceutical purchases. The overall U.S. pharmaceutical industry is estimated at $330 billion.
- Mail Order Pharmacy and Delivmeds Mobile App: The company provides a full-service mail order pharmacy for U.S. consumers and the "Delivmeds" mobile app for same-day home delivery of prescriptions in the U.S. The broader U.S. healthcare market, where these services operate, is valued at nearly $4 trillion and is projected to expand.
- Integra Pharma Solutions, LLC (IPS): Through its subsidiary, Integra Pharma Solutions, Scienture functions as a licensed pharmaceutical wholesaler. IPS distributes branded, generic, and non-drug products to a wide range of healthcare entities across the United States, including government organizations, hospitals, clinics, and independent pharmacies.
AI Analysis | Feedback
Scienture (SCNX) is expected to drive future revenue growth over the next two to three years through several key initiatives:
- Growth and Increased Utilization of the TRxADE Platform: Scienture anticipates revenue growth by increasing the number of registered users and enhancing the utilization rate of its web-based TRxADE platform, which facilitates transactions between independent pharmacists and drug distributors. The company aims to onboard more independent pharmacies, with a target of approximately 24,000 in the U.S., and is currently adding over 100 pharmacies per month.
- Launch and Commercialization of New Pharmaceutical Products: A significant driver is the continued development, launch, and commercialization of novel specialty pharmaceutical products. Scienture has recently commenced commercial sales of its Arbli oral suspension, which is expected to boost revenue. Additionally, the company plans to advance its pharmaceutical pipeline, focusing on central nervous system (CNS) and cardiovascular system (CVS) diseases, with product candidates such as SCN-102, SCN-104, SCN-106, and SCN-107.
- Strategic Partnerships and Mergers & Acquisitions (M&A): Scienture is pursuing strategic partnerships and M&A opportunities within the drug value chain to strengthen its market position. These collaborations are anticipated to contribute to revenue growth by expanding market reach and enhancing product offerings.
- Integration of Artificial Intelligence (AI) Technology: The company is exploring intriguing developments and the potential integration of cutting-edge AI technology into its offerings. This initiative is aimed at rejuvenating revenue streams and unlocking new opportunities within the industry.
- Expansion of Pharmaceutical Services and Market Reach: Scienture plans to increase its share of pharmacist drug purchasing and broaden its product offerings by adding more stock-keeping units (SKUs). Furthermore, the company intends to expand its mail-order licenses to all 50 states and scale its Delivmeds service for nationwide consumer delivery. These expansions are designed to extend its market presence and diversify revenue streams.
AI Analysis | Feedback
Share Issuance
- In August 2025, Scienture priced a registered direct offering of 3,225,000 shares of common stock at $1.20 per share, anticipating gross proceeds of approximately $3.9 million.
- In July 2025, the company secured approximately $1.2 million in bridge funding through the issuance of common stock to institutional or accredited investors, as part of an approved capital raise of up to $3 million, with shares issued at $1.59 each.
- As of October 2025, Scienture increased its capacity to sell common stock under an equity distribution agreement to an aggregate offering price of up to $9,592,009, having already sold approximately $13,252,250 in gross proceeds of securities over the prior 12 months.
Inbound Investments
- Scienture secured approximately $1.2 million in bridge funding in July 2025 from institutional or accredited investors.
- The company received approximately $3.9 million in gross proceeds from a registered direct offering to institutional investors in August 2025.
Outbound Investments
- Scienture's net loss from continuing operations increased in 2024, primarily due to higher operating expenses following the acquisition of Scienture LLC.
Capital Expenditures
- In its fiscal year ended December 31, 2024, Scienture Holdings Inc. reported a net cash outflow from investing activities of $2,308,016, which included capital expenditures of $12,713.
- For the fiscal year ended December 31, 2023, the company reported capital expenditures of $24,000.
- Capital expenditures for the fiscal year ended December 31, 2022, were $8,141.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Scienture Earnings Notes | ||
| Day 5 of Loss Streak for Scienture Stock with -70% Return (vs. -87% YTD) [10/30/2025] | Notification | |
| How Low Can Scienture Stock Really Go? | Return |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Scienture
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 161.75 |
| Mkt Cap | 325.9 |
| Rev LTM | 61,215 |
| Op Inc LTM | 18,904 |
| FCF LTM | 11,712 |
| FCF 3Y Avg | 11,306 |
| CFO LTM | 15,071 |
| CFO 3Y Avg | 14,817 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.2% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 7.9% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 25.4% |
| Op Mgn 3Y Avg | 25.1% |
| QoQ Delta Op Mgn LTM | 1.7% |
| CFO/Rev LTM | 23.5% |
| CFO/Rev 3Y Avg | 22.6% |
| FCF/Rev LTM | 18.4% |
| FCF/Rev 3Y Avg | 17.1% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integra | 1 | 5 | 3 | 10 | 1 |
| Scienture | 0 | ||||
| Unallocated | 0 | 0 | 0 | 0 | |
| Superlatus | 0 | ||||
| Trxade, Inc. | 5 | 5 | 6 | 5 | |
| Community Specialty Pharmacy, LLC (CSP) | 2 | 2 | 2 | ||
| Total | 1 | 10 | 10 | 17 | 7 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Scienture | 0 | ||||
| Integra | -1 | -1 | -3 | -1 | -0 |
| Unallocated | -17 | -5 | -4 | -4 | -2 |
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 3 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -1 | -0 | ||
| Total | -18 | -4 | -5 | -3 | -0 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Unallocated | 12 | 1 | 3 | 5 | 3 |
| Integra | 0 | 0 | 1 | 3 | 0 |
| Scienture | 0 | ||||
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 2 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -0 | 0 | ||
| Total | 13 | 4 | 6 | 10 | 6 |
Price Behavior
Price Behavior
| Market Price | $0.50 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/26/2009 | |
| Distance from 52W High | -89.3% | |
| 50 Days | 200 Days | |
| DMA Price | $0.58 | $0.99 |
| DMA Trend | down | down |
| Distance from DMA | -14.3% | -50.0% |
| 3M | 1YR | |
| Volatility | 738.9% | 387.3% |
| Downside Capture | 266.89 | 319.02 |
| Upside Capture | 233.63 | 44.89 |
| Correlation (SPY) | 8.9% | 8.5% |
SCNX Betas & Captures as of 12/31/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.07 | 1.00 | 5.08 | 3.72 | 1.70 | 1.23 |
| Up Beta | 2.42 | 2.10 | 0.39 | 2.49 | 0.33 | 0.11 |
| Down Beta | 0.94 | -0.56 | 2.04 | 1.50 | 2.11 | 2.01 |
| Up Capture | 219% | -66% | 130% | 25% | 6% | 42% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 15 | 23 | 52 | 98 | 322 |
| Down Capture | 494% | 251% | 328% | 265% | 161% | 111% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 12 | 25 | 39 | 71 | 147 | 415 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| SCNX vs. Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| SCNX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -88.2% | 10.1% | 15.3% | 75.7% | 3.6% | 7.5% | -7.9% |
| Annualized Volatility | 385.0% | 14.1% | 19.3% | 20.3% | 15.3% | 16.8% | 34.3% |
| Sharpe Ratio | 0.25 | 0.45 | 0.61 | 2.67 | 0.03 | 0.26 | -0.08 |
| Correlation With Other Assets | 1.8% | 8.6% | 0.4% | 13.4% | 6.2% | 14.1% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| SCNX vs. Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| SCNX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -60.7% | 7.0% | 13.8% | 20.4% | 11.5% | 6.0% | 21.1% |
| Annualized Volatility | 219.6% | 13.1% | 17.1% | 15.7% | 18.7% | 18.8% | 48.0% |
| Sharpe Ratio | 0.20 | 0.33 | 0.65 | 1.05 | 0.50 | 0.22 | 0.47 |
| Correlation With Other Assets | 3.3% | 8.2% | 3.3% | 7.6% | 7.2% | 6.2% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| SCNX vs. Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| SCNX | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -39.1% | 8.0% | 15.3% | 15.4% | 8.0% | 5.7% | 70.5% |
| Annualized Volatility | 269.3% | 14.7% | 18.0% | 14.9% | 17.6% | 20.8% | 55.7% |
| Sharpe Ratio | 0.66 | 0.41 | 0.73 | 0.86 | 0.37 | 0.24 | 0.91 |
| Correlation With Other Assets | 2.1% | 5.4% | 2.6% | 3.4% | 4.2% | 3.8% | |
ETFs used for asset classes: Sector ETF = XLP, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/27/2023 | -20.8% | -38.4% | -29.5% |
| 11/7/2022 | -6.9% | -11.5% | -47.0% |
| 7/25/2022 | -6.9% | -10.3% | -24.1% |
| 3/28/2022 | 12.0% | -5.6% | -24.8% |
| 10/25/2021 | -0.7% | 1.2% | -18.9% |
| 7/26/2021 | -10.8% | -1.3% | -6.8% |
| 3/29/2021 | -27.1% | -28.5% | -38.7% |
| 10/26/2020 | -18.5% | -33.9% | -21.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 2 | 1 | 1 |
| # Negative | 7 | 8 | 8 |
| Median Positive | 7.6% | 1.2% | 16.4% |
| Median Negative | -10.8% | -10.9% | -24.5% |
| Max Positive | 12.0% | 1.2% | 16.4% |
| Max Negative | -27.1% | -38.4% | -47.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/12/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/12/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/26/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/06/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/09/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 06/26/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 04/22/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 01/16/2024 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/18/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/15/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/27/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/07/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 07/25/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/09/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/28/2022 | 10-K (12/31/2021) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.